newsfilter
← Latest News
Earnings Call Transcripts·

Ascend Wellness Holdings Q3 2026 Earnings Conference Call - Ascend Wellness Holdings, Inc.

AAWH

  • Financial Performance:

    • Net revenue reached $130 million, up 3.1% sequentially and 4.2% year-over-year, driven by retail sales growth to 75.2% of total revenue.
    • Adjusted EBITDA was $31.1 million with a margin expansion to 23.9% from 23.1% in Q2.
    • Adjusted gross profit margin expanded to 48.4% from 46.2% in the prior quarter.
    • Cash flow from operations was positive at $5.4 million despite a $19.1 million biannual interest payment; cash balance ended at $63.6 million.
    • Q3 saw a temporary decline in alternate (wholesale) revenue ($32.2 million) due to an Illinois union strike, which has since resolved with September showing the strongest wholesale month of the year.

  • Guidance and Future Outlook:

    • Q4 2026 revenue guidance is 1% to 2% sequential growth, tempered by seasonal discounting and ongoing price compression.
    • Adjusted EBITDA margin guidance for Q4 is expected to remain consistent with Q3's 23.9%.
    • Management anticipates a meaningful shift in demand as the federal "intoxicating hemp loophole" closes by the December deadline, potentially driving share into the regulated market.
    • Full-year 2026 CapEx remains on track at approximately $20 million.
    • Long-term goal to become the number one player in all core markets remains unchanged.

  • Business Segments and Product Lines:

    • Retail footprint expanded to 61 stores (including partner locations), surpassing the 60-store target ahead of schedule.
    • New store transactions grew 6% sequentially and 14.9% YoY, with New Jersey transactions up 37% YoY.
    • Loyalty members now account for 86% of all transactions; Ascend Pay was used in 11% of transactions.
    • Brand portfolio: Ascend is #2 in combined sales/units across IL, NJ, MA; Ozone is #3 in flower sales; Simply Herb Vapes reached #8 in core markets; High Wired is #1 in infused flower and #2 in infused pre-rolls in NJ.
    • Product innovations included 103 new SKUs, the launch of Ozone Signature premium flower, F&Tabs edibles, and upgraded gummy formulas.
    • International expansion: Secured licensing deal with Atlantic Cultivation to bring High Wired and Ozone Liquid Diamond Vapes to Canada starting Q1 2027.

  • Market and Competitive Landscape:

    • Ascend is gaining vertical integration share, converting wholesale volume to higher-margin retail sales across its network.
    • Market share increased in New Jersey (+14% QoQ) and across most footprint, excluding Illinois due to the prior quarter's strike.
    • Regulatory environment: Massachusetts voters rejected adult-use repeal (75% "no"), reinforcing market durability; DEA rescheduling hearing concluded, with state-level medical reclassification (Schedule III) already effective.
    • Production efficiency improved with yield up 21% since Q1 2025 and premium flower output increasing per square foot.

  • Risks and Challenges:

    • Ongoing price compression in the cannabis market remains a headwind for top-line growth.
    • Potential regulatory shifts regarding the federal hemp loophole and rescheduling timing remain uncertain.
    • Local and state regulatory challenges in New Jersey have delayed two partner store openings, though they are expected early next year.
    • Illinois union strike previously impacted July wholesale deliveries, though operations have normalized.

  • Management Commentary and Tone:

    • Tone was confident and positive, citing "strong execution" across all three strategic pillars: retail densification, customer-first model, and CPG strategy.
    • Management emphasized that reaching the 60-store target was a milestone and that M&A conversations are active with a robust pipeline.
    • Emphasis placed on capital discipline, achieving a 30%+ return on invested capital, and maintaining non-dilutive funding sources.
    • CEO Sam Brill and CFO Roman Nemchenko highlighted that the shift to a retail-heavy mix is by design to improve margins and reduce reliance on wholesale for excess biomass.

  • Analyst Questions and Answers:

    • Wholesale Recovery: Management clarified that wholesale revenue decline is strategic as biomass is redirected to higher-margin retail channels; wholesale momentum is expected to improve but remains secondary to retail growth.
    • Q4 Guidance vs. Store Growth: Management explained the conservative 1-2% Q4 revenue guide accounts for historical seasonal price pressure in December and the ramp-up curve for new stores, with full impact expected in Q1 2027.
    • G&A Spend: The Q3 increase in SG&A was primarily attributed to a $2 million sequential incentive compensation accrual; excluding this, spend is consistent with sales growth.
    • Store Economics & M&A: Current store acquisitions are performing in line with conservative underwriting assumptions; the company maintains a high bar for capital allocation to preserve free cash flow.
    • Canada Expansion: The Canadian deal was an opportunistic, low-risk entry to test brand viability internationally, not a core part of current projections.

  • Other Key Points:

    • Shareholders approved a reverse stock split to facilitate future uplisting to a major U.S. exchange.
    • Ascend secured $11 million in non-dilutive mortgage financing (8.5% interest, 2031 maturity) to fund further retail densification.
    • Average Google rating across the network is 4.66, with new customer traffic up 19%.
    • The company is expanding vertically in Massachusetts to include a full medical license upon regulatory approval of recent acquisitions.